


WISC 2012 Hyderabad, India
6-9 December
2012 WAO International Scientific Conference


WAO
A World Federation of Allergy, Asthma
and Clinical Immunology Societies

Management and a Structured approach to Allergic Rhinitis in a clinical setting

Dr Neelam Vaid
Associate Professor,
Dept of ENT,
K.E.M. Hospital,
Pune, India




Objectives



- Epidemiology
- Making the right diagnosis
- Treatment guidelines on the basis of evidence



Definition




Symptomatic disorder of the nose induced after allergen exposure by an IgE mediated inflammation of the membranes lining the nose.

Prevalence


- 20% prevalence rate worldwide
- **Asia – increased from 5% TO 45%**
- All ages are affected.
- Onset mean age 8 – 11 yrs. 80% develops by age 20 yrs.
- Children: 40% prevalence subsequently decreases with age.



Impact



Donald Gemson, Benjamin Eng. *The Impact of Allergic Rhinitis On Employee Health and Productivity, Business and Health* August 2004;22.



ARIA guidelines: classification of allergic rhinitis

Intermittent symptoms

- <4 days per week or
- <4 weeks

Persistent symptoms

- >4 days per week and
- >4 weeks

Mild symptoms

- Normal sleep
- Normal daily activities
- Normal work and school
- No troublesome symptoms

Moderate-severe symptoms ≥ 1 items

- Abnormal sleep
- Impairment of daily activities, sport, leisure
- Problems caused at school or work
- Troublesome symptoms

AR and Comorbid airway disease



Spector, *J Allergy Clin Immunol*, 1997;99:S773-S780.

Comorbidities implications on treatment

- Treatment of allergic rhinitis may be important for its own sake and for its impact on other upper and lower airway diseases

Leynaert et al. *J Allergy Clin Immunol*. 1999;104:301-304. Corren. *J Allergy Clin Immunol*. 1997;99:S781-S786. Spector. *J Allergy Clin Immunol*. 1997;99:S773-S780. Storms et al. *J Allergy Clin Immunol*. 1997;99:S820-S824. Sporik et al. *N Engl J Med*. 1990;323:502-507. Lundback. *Clin Exp Allergy*. 1998;28(suppl:2):3-10.

- **History and Examination**
- Skin prick test
- Allergy blood test – RAST, fluorescence enzyme labelled assays
- Nasal Provocation test



Making a diagnosis of allergic rhinitis (AR) - symptoms

- Sneezing, itchy nose, itchy palate (AR very likely)
 - Seasonal? (pollens or mould spores)
 - At home? (pets or house dust mite)
 - Improves on holiday?
- Rhinorrhoea
 - Clear (AR likely)
 - Yellow (AR or infection)
 - Green, blood tinged or unilateral (other cause)

Making a diagnosis of allergic rhinitis (AR) - symptoms

- Nasal obstruction
 - Unilateral (AR unlikely) vs bilateral
- Nasal crusting
 - AR unlikely
- Eye symptoms
 - Often seen with AR, especially seasonal AR
- LRT symptoms
 - Cough may be caused by AR
- Other symptoms
 - Snoring, sleep disturbance, mouth breathing, "nasal voice" (not v. specific for AR)

- **Sneezers & runners** – Intermittent Atopy family history




- **Blockers** – Persistent Sinusitis Higher sensitization to fungi (62%) and house dust mite

Ashok Shah & Ruby Pawankar
ASIAN PACIFIC JOURNAL OF ALLERGY AND IMMUNOLOGY (2009) 27: 71-77

Examination

Allergic shiners



Allergic salute



Transverse nasal crease



Skin testing?



NO

- Hx suggestive for AR
- Trial of appropriate therapy successful
- Symptoms mild and easily managed
- Mechanical, anatomical, or infectious causes

YES

- Poor response to therapeutic trial
- Persistent &/or mod severe AR
- QOL affected
- Strong desire for immunotherapy

- In India commonest allergen on skin testing is pollens, fungi (*A.flavus*) and house dust mite (*Dermatophagoides farinae*)



Ashok Shah & Ruby Pawankar
 ASIAN PACIFIC JOURNAL OF ALLERGY AND IMMUNOLOGY (2009)
 27: 71-77

Treatment guidelines

- Patient education
- Allergen avoidance
- Pharmacotherapy
- Immunotherapy

Allergic rhinitis and its impact on asthma guidelines 2001

Treatment

- **Education**
 - Nature of disease
 - Symptoms
 - Complications (eg sinusitis, otitis media, later asthma)
 - Allergen avoidance
 - **Realistic expectations of treatment**
 - **Drug treatment and potential sideeffects**
 - Compliance and correct technique

Allergen avoidance

- Good evidence for pets (but takes time for cats), horses and certain occupational allergens
- Weak evidence for house dust mite avoidance, most benefit with multiple interventions
- Some evidence for pollen filters and nasal air filters

- Mite proof pillow covers and bedding
- Wash bedding once a week in hot water
- Dusting with a wet cloth
- Carpets to be vacuumed (HEPA filter)
- Wooden and leather furniture
- Pollen filters – window filter
- Nasal filters- activated carbon and cellulose





Ethnic Nasal Filter




PHARMACOTHERAPY

<h3>Topical Nasal Treatments</h3> <ul style="list-style-type: none"> • Corticosteroids • Antihistamines • Chromones • Anticholinergics • Decongestants 	<h3>Oral Treatments</h3> <ul style="list-style-type: none"> • Antihistamines • Corticosteroids • Antileukotrienes • Decongestants
---	---




Treatment plan

- Duration and severity of symptoms.
- Type of symptoms



Intermittent mild

- Oral antihistamine OR intranasal H1 blocker

↓

Not better

↓

Intranasal CS

Intermittent mod severe Persistent mild

Intranasal steroids

↓

Persists for 2 – 4 weeks

↓

Check use/compliance
Oral CS – One dose

↓


Improves

↓

Continue for 1 month

Nasal decongestants for congestion
Nasal antihistaminics for rhinorrhoea
Oral antihist for persistent nasal ocular symptoms

Persistent moderate/severe




Allergic rhinitis: Symptom related ARIA treatment guidelines

	Congestion	Rhinorrhoea	Itching / sneezing	Duration
Intranasal steroids	+++	+++	+/+++	12-48 h
Oral antihistamines	+	++	+++/>+	12-24 h
Oral decongestants	+	-	-/	3-6 h
Intranasal cromones	+	+	+/+	2-6 h
Anticholinergics	-	++	-/	4-12 h
Antileukotrienes	++	+	-/	Not reported

Bousquet et al. Allergy 2002; 57: 841-855.
van Cauwenberge et al. Allergy 2000; 55: 116-134.


Nasal Sprays

- Nasal steroids
- Cromolyn - nasal crom
- Oxymetazoline
- Ipratropium (anticholinergic)
- Nasal saline – jal neti



Nasal Steroids

- Mometasone
- Fluticasone
- Budesonide
- Beclomethasone



Fluticasone fluorate - < 0.5% bioavailability.
Can be used in children more than 2 yrs of age.

TABLE 1
Intranasal corticosteroid preparations

STERIOD PREPARATION	AGE INDICATED (YEARS)	SYSTEMIC BIOAVAILABILITY (%)	AVERAGE WHOLESALE PRICE*
First-generation formulations			
Beclomethasone dipropionate (Beconase AQ)	> 6	17	\$77.56 (25-g inhaler)
Flunisolide (Nasarel)	> 6	20-50	\$69.73 (25-ml bottle)
Triamcinolone acetate (Nasacort AQ)	> age 6	22	\$75.85 (16.5-g inhaler)
Second-generation formulations			
Budesonide (Rhinocort Aqua)	> 6	11	\$76.13 (8.6-g bottle)
Fluticasone propionate (Flonase)	> 4	< 2	\$70.87 (16-g bottle)
Mometasone furoate (Nasonex)	> 2	< 0.1	\$74.47 (17-g inhaler)

*Prices from Red Book 2005

MODIFIED FROM HADLEY JA, KAVURU MS, ANON JB, PIEN LC. DIAGNOSIS AND MANAGEMENT OF RHINITIS AND RHINOSINUSITIS. 3RD ED. NEW YORK: PROFESSIONAL COMMUNICATIONS INC; 2005:65, WITH PERMISSION.

INS – is one better than the other

- No clear evidence to support the suggestion that one steroid spray is more effective than another.
- All the sprays have a similar side-effect profile; the commonest being epistaxis with a reported incidence between 17 and 23 per cent. The placebo spray had an appreciable rate of epistaxis of between 10 to 15 per cent.
- Fluticasone causes a reduction in endogenous cortisol secretion but no significant adrenal suppression was seen with triamcinolone, beclomethasone, budesonide or mometasone.
- There is little evidence that skeletal growth is restricted by the administration of topical nasal steroid sprays.

A.N. Waddell et al : *The Journal of Laryngology & Otology* Volume 117 / Issue 11 / November 2003, pp 843-845

FAQ

- Effect on DM, HT – not reported. No study has addressed this issue.
- Effect on Glaucoma – no association
- Childrens growth – affected by beclomethasone dipropionate
- Effect on HPA axis – dexamethasone, betamethasone
- Adrenal suppression – not reported in children. In adults with budesonide and fluticasone propionate

Combination therapy

- Intranasal CS with antihistamines / antileukotrienes : no more effective than Intranasal CS alone
- Fluticasone with azelastine more effective than either agent alone
- Recommended to begin with single agent and use combination for severe or persistent symptoms

PAEDIATRIC ALLERGIC RHINITIS

- 4 years and older should be treated as for adults
- Children (>4) with AR and Asthma can be treated with combination of newer generation topical and inhaled corticosteroids with low risk of complications
- Diagnosis in smaller children is difficult as can have up to 6 to 8 colds per year
- Small children – oral antihistamines, saline sprays and corticosteroids if symptoms severe

AR RHINITIS IN PREGNANCY

- Nasal Saline
- Nasal corticosteroids – all Category C except Budesonide which was recently reassigned B – nasal steroid of choice
- Antihistamines – chlorpheniramine, loratadine and cetirizine are B
- Oral steroids - C
- Decongestants - C

Immunotherapy

- Rise in IgG “blocking” antibodies
- Reserved for patients who find it difficult to avoid allergens but do not respond adequately to pharmacologic therapy
- Children > 7 years old

Summary

- Allergic rhinitis is common, often persistent, but often overlooked
- Diagnosis is relatively straightforward if the right questions are asked
- Mainstays of treatment are allergen avoidance, oral antihistamines and intranasal corticosteroids
- Strong link with asthma

Oral (H1) antihistamines

Age	Non-sedating	Sedating
> 6 months		Trimeprazine
> 1 year	Desloratidine	Hydroxyzine Chlorphenamine
> 2 years	Cetirizine (SAR only) Loratidine Levocetirizine	Promethazine Ketotifen
> 6 years	Fexofenadine (SAR only) Cetirizine	

Oral antihistamines

- Effect mainly on itch, sneeze and rhinorrhoea, less on congestion
- Effects on other sites eg eyes, palate
- Acts within 2-4 hours
- Sedation, otherwise few adverse events
- Also available topically, azelastine, which has quick onset of action, but local irritation and taste disturbance a problem

Nasal corticosteroids

- Acts on all symptoms of AR
- Often improves eye symptoms
- Onset of action within 6-8h, maximal effect may not be seen for 2 weeks
- Once or twice daily dosing
- Systemic absorption least for mometasone and fluticasone with reassuring safety data
- Local irritation (worse with alcohol containing preparations), sore throat and epistaxis affect about 10%

Oral antileukotrienes

- Not as effective as intranasal CS and antihistamines
- To be considered for second/third line therapy


Other therapies

- Oral anti-leukotrienes
 - Montelukast licensed for SAR + asthma > 6 months, Zafirlukast > 12 y
- Topical cromones
 - Sodium cromoglicate (qds)
- Topical anti-cholinergics
 - Ipratropium given tds may help rhinorrhoea
- Nasal saline douches
- Intranasal decongestants
 - Short term only (useful at start of therapy), rebound symptoms
- Allergen immunotherapy
- Anti-IgE therapy

One airway, one disease?

Most patients with asthma have rhinitis


- Approximately 80% of patients with asthma have rhinitis



Leynaert et al 2000

Allergic rhinitis is a risk factor for asthma

- Allergic rhinitis increases the risk of asthma ~3-fold



Link between allergic rhinitis and asthma

- Some patients with allergic rhinitis report increased asthma symptoms during the pollen season
- Rhinitis and asthma involve a common respiratory mucosa
- Inflammation is involved in the pathogenesis of both allergic rhinitis and asthma
- Allergic reactions in the nasal mucosa can potentially worsen asthmatic inflammatory processes in the lower airways
- Allergen specific immunotherapy for rhinitis reduces development of asthma in children

How can rhinitis worsen asthma?

- Nasal blockage leads to mouth breathing and exposure to cold, dry air, and an increase in allergens in the lower respiratory tract
- Nasal challenge induces release of bone marrow eosinophils into the systemic circulation, which in turn can result in an inflammatory response within the entire respiratory tract
- Rhinitis causes bronchial hyperreactivity
- Neurogenic reflexes?
- Nitric oxide changes?

Treating allergic rhinitis cuts asthma costs

- 61% fewer hospitalisations in treated patients

